What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. - Wikidata - awgldk - TriplyDB

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

http://www.wikidata.org/entity/Q53262525

about

Vitamin A and Alzheimer's disease Alzheimer mechanisms and therapeutic strategies γ-Secretase inhibitors and modulators.New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Amyloid-β and APP deficiencies cause severe cerebrovascular defects: important work for an old villain DBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's disease.Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ-secretase complexes.Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction.Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model.The impact of human and mouse differences in NOS2 gene expression on the brain's redox and immune environment.Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.The γ-secretase complex: from structure to function.Cognitive health begins at conception: addressing dementia as a lifelong and preventable condition Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease.Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.Alzheimer's disease: a clinical practice-oriented review.Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice.The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation.Neurotoxicity of biologically targeted agents in pediatric cancer trials Cellular and animal models for high-throughput screening of therapeutic agents for the treatment of the diseases of the elderly in general and Alzheimer's disease in particular(†).Purinergic receptors as potential therapeutic targets in Alzheimer's disease.Effects of the γ-secretase inhibitor semagacestat on hippocampal neuronal network oscillation.Why our patients (and we) need basic science research Involvement of presenilin holoprotein upregulation in calcium dyshomeostasis of Alzheimer's disease.γ-Secretase inhibition promotes fibrotic effects of albumin in proximal tubular epithelial cells.Disease-modifying drugs in Alzheimer's disease.Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Alzheimer's disease: the challenge of the second century.Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.Biomarkers for Alzheimer's disease: showing the way or leading us astray?Animal models of Alzheimer disease.Aiming at neuroblastoma and hitting other worthy targets.Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Gamma secretase inhibitors: a patent review (2013 - 2015).γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct.Production of active glycosylation-deficient γ-secretase complex for crystallization studies.Discovery of a Potent Pyrazolopyridine Series of γ-Secretase Modulators.Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.

P2860

Q22242414-1F77932E-E847-4087-97C6-5D420ACF1984 Q22252311-D8279130-CEF1-4009-A0F5-B62C810B9D5C Q26830462-AB0272D9-C86A-4439-92F8-F83471ED6593 Q26866006-29C3CC86-D4AE-4938-9E0C-C74957F9D06E Q27305806-10285BF5-7A00-4377-BF2D-32AC6D1E9833 Q30412535-9BB33D7A-0C59-409B-BCB2-DDC8DA3BDAD0 Q31057900-16747EAC-2A0F-483D-9437-5D5F10043050 Q34073334-66DB6B9A-C69D-493C-836A-CD2D23495FBD Q34157421-F832A999-4A7A-48C6-98FB-00DEA9F938D5 Q34584761-40518AF4-BBFE-4B5F-B9CB-591FE74E2650 Q34656871-6BDD7B40-3159-4E94-BD14-E002EEB39B6D Q34677532-FE25DD33-91B0-4D64-9A8C-A17734E21883 Q35046906-05C28689-342B-4033-A83F-2E943159A4A4 Q35052443-D2313232-9CDD-48F1-9371-125BC3A95E81 Q35758963-FB5D7316-424F-4ACB-B312-6E3B94CDF333 Q35899503-6A1EEA9E-8EED-46C8-B851-C1EE1C7A13F9 Q36378706-72B57074-54AC-4175-8BF1-05B2AA37A740 Q36562023-DD05A772-980D-40A0-93A0-9B0915979C17 Q36766221-4C2FAF40-3193-49C2-8385-2AB49823FAD9 Q36837509-5AA56AE5-19AC-44A9-8402-F50B043F0881 Q36844881-480BEBA8-02AB-47CB-A53B-C73EEB37165D Q36928744-84E105C5-AF92-4598-9837-0D54AD57B042 Q37027326-54F85C90-C640-439F-B8E5-2729EAC78E95 Q37293997-17EAF363-F939-4115-AEEA-AF71779CE787 Q37318868-048A0AEF-8033-4430-8DFB-70F3590E10C2 Q37390739-EB409C2D-277A-4147-9048-7C3FB1FE4F6F Q37559812-B589A074-4D77-48DF-BAA5-073CC67CE796 Q37862502-2DA06C41-597E-444A-B59D-E1A837A4F8F6 Q37987587-6CB28C9D-63BE-4B4B-ACAF-3C8021DE88AA Q38024256-50704D24-4242-483A-BC3A-8601ECE76EAD Q38045853-92507D45-077D-4212-B81A-E6D7BFE4D499 Q38098145-F22004AC-AD95-4657-8AFC-5F34B3A1D8FD Q38123209-EBD7A357-6F05-4E9C-A6EC-C22713E29355 Q38127470-07758F32-4575-4C1C-ABB3-27EFEE5631CF Q38738605-0E52DD7B-1BF0-4C6B-9819-805083DBDD22 Q38766437-A2E5ECEE-3CBD-46EE-9B9D-D4F938498366 Q38865583-66D249D8-C89D-4565-A1C6-65A282F66DBD Q39514771-AD1B2945-D0B9-4E1B-A54E-26418FE824EB Q39629610-5EF2817C-12F8-4705-86E7-EA5146B809EB Q39728463-67FB26B0-B8C8-4BDF-B12E-91B61361B88D

P2860

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

http://www.wikidata.org/entity/Q53262525

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

@en

What the halted phase III γ-secretase inhibitor trial may

@nl

type

label

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

@en

What the halted phase III γ-secretase inhibitor trial may

@nl

prefLabel

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

@en

What the halted phase III γ-secretase inhibitor trial may

@nl

P1433

Q53262525-03A23F65-4D53-4677-9C7B-26360577E0BE

P1476

Q53262525-20A225DD-47C3-4E42-AAC0-07A9539502A1

P2093

Q53262525-CD604249-E520-4FC1-BB50-68D844151F40

P2860

Q53262525-03EA2CE9-95F7-4EC8-9942-841F3310B306

Q53262525-214BBB93-2C2C-440F-B22E-4C1B54F16F88

Q53262525-3429C7C8-67AE-4EE5-96B6-8B9814B7B46D

Q53262525-3B5E53FC-DFD4-4A95-84E7-5598A86EC50C

Q53262525-4D9F2148-6BB7-411D-A785-3D1E3BBAE34F

Q53262525-560544BC-1E40-4A53-B3B5-2A61589C66E3

Q53262525-5CE77F8C-76C3-42C2-9949-7D75B82626E4

Q53262525-621585B5-8985-4738-AB2C-0ADF713AC000

Q53262525-662BBB34-F0AC-4312-A0A2-8E98B108877D

Q53262525-7571BA81-8D04-49A5-B66C-328A3F067D23

P304

Q53262525-4649E58B-E1F3-4E80-AB64-15C04995DD03

P31

Q53262525-8440995B-0476-4D6B-B895-D992980F6A2A

P356

Q53262525-E8F236A5-7E50-4BC8-A603-23DF9152D833

P433

Q53262525-C2574A65-FBFD-458B-B45A-359990F58278

P478

Q53262525-1D2114DC-7808-4A2E-89A3-60061C088B8C

P50

Q53262525-6B4033EE-BA90-4204-BC64-5C78DA9D138E

P577

Q53262525-E74CAAED-8D64-457D-AEF7-141972940CF4

P5875

Q53262525-DD12516B-FCE2-45CD-A5C8-C705269E3CEB

P698

Q53262525-7237E62D-D445-4808-8C76-F0AC6AB660A4

P921

Q53262525-C4B3A56E-CF5D-47DF-803F-37FC3AA4E3D0

P356

P1433

Annals of Neurology

P1476

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us

@en

P2093

Nina F Schor

http://www.w3.org/2001/XMLSchema#string

P2860

Notch inhibits apoptosis by direct interference with XIAP ubiquitination and degradation

Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway

Presenilin/gamma-secretase cleaves CD46 in response to Neisseria infection

Modulation of gamma-secretase specificity using small molecule allosteric inhibitors.

Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism.

Expression of the low-affinity nerve growth factor receptor enhances beta-amyloid peptide toxicity.

The p75 neurotrophin receptor in human development and disease.

Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)

Structure and function of gamma-secretase.

P304

237-239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.22365

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50349468

http://www.w3.org/2001/XMLSchema#string

P698

21387368

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial